AbCellera Biologics Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ABCL Nasdaq 2830 www.abcellera.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AbCellera Biologics Inc.

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025 - Jul 7th, 2025 2:05 pm
Truist Financial Lowers PT on AbCellera Biologics (ABCL) to $10 From $28, Keeps a Buy Rating - Jul 7th, 2025 7:11 am
Village Farms International And 2 Other Promising Penny Stocks For Your Watchlist - Jul 4th, 2025 12:05 pm
We're Interested To See How AbCellera Biologics (NASDAQ:ABCL) Uses Its Cash Hoard To Grow - Jun 30th, 2025 6:45 am
AbCellera Biologics Secures Patent Validity Affirmation for Microfluidic Cell Culture Technology - Jun 25th, 2025 2:09 am
AbCellera Biologics Inc. (ABCL): A Bull Case Theory - Jun 9th, 2025 7:13 am
ABCELLERA BIOLG (ABCL) Upgraded to Buy: Here's Why - Jun 3rd, 2025 10:00 am
AbCellera Biologics And 2 Other Promising Penny Stocks To Watch - Jun 3rd, 2025 6:05 am
Why AbCellera Biologics Stock Raced Nearly 6% Higher Today - Jun 2nd, 2025 4:45 pm
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 - May 30th, 2025 11:00 am
AbCellera Biologics Inc. (ABCL): Analysts See 474% Upside Potential - May 21st, 2025 9:21 am
Analyst Forecasts Just Became More Bearish On AbCellera Biologics Inc. (NASDAQ:ABCL) - May 15th, 2025 6:57 am
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause - May 14th, 2025 3:00 pm
AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit - May 12th, 2025 1:30 pm
AbCellera Biologics First Quarter 2025 Earnings: Revenues Disappoint - May 10th, 2025 6:51 am
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting - May 9th, 2025 5:30 pm
AbCellera Biologics Inc (ABCL) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... - May 9th, 2025 1:50 am
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates - May 8th, 2025 4:05 pm
AbCellera Reports Q1 2025 Business Results - May 8th, 2025 2:05 pm
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025 - Apr 29th, 2025 1:00 pm